A Phase 2 interventional study of Topical endoxifen and Placebo in Mammographic Breast Density, sponsored by Atossa Therapeutics, Inc.. Completed at 1 site in Sweden. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-12.
Sponsored by Atossa Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the pilot trial was to estimate time to mammographic density change. The primary objective was to determine the effect size of the breast density change between topical placebo and two doses of topical endoxifen.
Atossa Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
Drug: Placebo
10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
Drug: Topical endoxifen
20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
Drug: Topical endoxifen
topical solution
topical
Change in Mammographic Breast Density At Study Exit
Change, on an individual level, in mammographic breast density, measured at 6 months or when exiting from the study (baseline screening mammography)
Time frame: From baseline to study exit up to 6 months
| Milestone | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day |
|---|---|---|---|
| Started | 30 | 30 | 30 |
| Completed | 23 | 2 | 0 |
| Not completed | 7 | 28 | 30 |
Change, on an individual level, in mammographic breast density, measured at 6 months or when exiting from the study (baseline screening mammography)
| percent change from baseline | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day |
|---|---|---|---|
| Change in Mammographic Breast Density At Study Exit | -1.85 ± 5.58 | -2.14 ± 6.50 | -3.75 ± 7.81 |
Collected over Up to 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | 0/30 (0%) | 0/30 (0%) | 27/30 (90%) |
| Topical Endoxifen 10mg/Breast/Day | 0/30 (0%) | 0/30 (0%) | 28/30 (93.3%) |
| Topical Endoxifen 20mg/Breast/Day | 0/30 (0%) | 0/30 (0%) | 27/30 (90%) |
| Event | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day |
|---|---|---|---|
| Rashes on breast skinSkin and subcutaneous tissue disorders | 12/30 | 21/30 | 26/30 |
| Sexual feeling decreasedPsychiatric disorders | 23/30 | 19/30 | 15/30 |
| Itching from the breast skinGeneral disorders | 6/30 | 21/30 | 22/30 |
| Dryness vaginalReproductive system and breast disorders | 22/30 | 22/30 | 13/30 |
| Night sweatsReproductive system and breast disorders | 21/30 | 13/30 | 14/30 |
| Menopausal hot flushesReproductive system and breast disorders | 19/30 | 14/30 | 16/30 |
| Painful intercourseReproductive system and breast disorders | 19/30 | 16/30 | 14/30 |
| Fragile mucous membranesGeneral disorders | 18/30 | 14/30 | 14/30 |
| Muscle cramps (e.g. in legs)Musculoskeletal and connective tissue disorders | 18/30 | 11/30 | 11/30 |
| HeadachesNervous system disorders | 17/30 | 11/30 | 5/30 |
| Age, Continuous(years) | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day | Total |
|---|---|---|---|---|
| Mean | 54.9 ± 6.01 | 56.9 ± 7.97 | 57.7 ± 8.41 | 56.5 ± 7.5 |
| Sex: Female, Male(Participants) | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day | Total |
|---|---|---|---|---|
| Female | 30 | 30 | 30 | 90 |
| Male | 0 | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Region of Enrollment(Participants) | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day | Total |
|---|---|---|---|---|
| Sweden | 30 | 30 | 30 | 90 |
| BMI(kg/m^2) | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day | Total |
|---|---|---|---|---|
| Mean | 24.9 ± 2.77 | 25.6 ± 3.57 | 25.2 ± 3.08 | 25.2 ± 3.1 |
| Blood pressure (systolic)(mm Hg) | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day | Total |
|---|---|---|---|---|
| Mean | 117.5 ± 12.1 | 123.7 ± 8.45 | 120.4 ± 10.1 | 120.5 ± 10.5 |
| Weight(kg) | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day | Total |
|---|---|---|---|---|
| Mean | 69.0 ± 7.33 | 69.8 ± 9.74 | 70.2 ± 9.31 | 69.7 ± 8.8 |
| Height(cm) | Control | Topical Endoxifen 10mg/Breast/Day | Topical Endoxifen 20mg/Breast/Day | Total |
|---|---|---|---|---|
| Mean | 166.6 ± 5.14 | 165.3 ± 6.38 | 167.0 ± 6.06 | 166.3 ± 5.9 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Sep 2018, 5 months.
Results were first posted in Jun 2021, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Endoxifen
Atossa Therapeutics, Inc.